tyrosine has been researched along with mci 9038 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakhos, M; Fareed, J; Jeske, WP; Lewis, BE; Leya, F; Walenga, JM; Wallis, DE | 1 |
| Corno, A; Horisberger, J; Marty, B; Mueller, X; von Segesser, LK | 1 |
| Goto, S; Ishida, H; Tamura, N | 1 |
| Allegretto, N; Barbera, F; Bird, JE; Giancarli, MR; Ogletree, ML; Schumacher, WA; Seiffert, D; Wong, P | 1 |
| Alexandrov, AV; Bavarsad Shahripour, R | 1 |
2 review(s) available for tyrosine and mci 9038
| Article | Year |
|---|---|
Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass.
Topics: Abciximab; Ancrod; Antibodies, Monoclonal; Anticoagulants; Arginine; Cardiopulmonary Bypass; Chondroitin Sulfates; Cross Reactions; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Factor Xa Inhibitors; Hemodilution; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Perfusion; Pipecolic Acids; Platelet Aggregation Inhibitors; Protamines; Sulfonamides; Thrombocytopenia; Thrombophilia; Thrombosis; Tirofiban; Tyrosine | 2001 |
Ancillary approaches to plasminogen activators.
Topics: Anticoagulants; Arginine; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Collateral Circulation; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hypothermia, Induced; Low-Level Light Therapy; Pipecolic Acids; Plasminogen Activators; Platelet Aggregation Inhibitors; Prospective Studies; Recombinant Proteins; Sulfonamides; Thrombolytic Therapy; Tirofiban; Tyrosine; Ultrasonic Therapy; Vasodilator Agents | 2012 |
3 other study(ies) available for tyrosine and mci 9038
| Article | Year |
|---|---|
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Anticoagulants; Antithrombins; Arginine; Blood Platelets; Drug Therapy, Combination; Female; Heparin; Hirudin Therapy; Humans; Immunoglobulin Fab Fragments; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombocytopenia; Tirofiban; Tyrosine | 1999 |
Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions.
Topics: Abciximab; Adult; Antibodies, Monoclonal; Anticoagulants; Arginine; Blood Platelets; Collagen; Eptifibatide; Fibrinolytic Agents; Hemorheology; Humans; Immunoglobulin Fab Fragments; In Vitro Techniques; Peptides; Pipecolic Acids; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2004 |
Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis.
Topics: Animals; Anticoagulants; Arginine; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Chlorides; Ferric Compounds; Guinea Pigs; Hemostasis; Male; Pipecolic Acids; Platelet Aggregation Inhibitors; Sulfonamides; Thrombosis; Tirofiban; Tyrosine | 2008 |